Mushrooms for Chronic Inflammation: Which Species Have the Evidence?

Mushrooms & Inflammation

17 Reishi clinical trials

A 2025 GRADE meta-analysis pooled 17 Reishi randomized controlled trials (971 participants) and found no significant effect on CRP or other inflammatory markers. The most-marketed anti-inflammatory mushroom has the weakest clinical record.

Jafari et al., Food Science and Nutrition, 2025

52 adults

Shiitake RCT: the only trial showing CRP improvement with a single mushroom species

971 participants

pooled in the Reishi meta-analysis that found no CRP effect

no effect

Reishi's impact on CRP, TNF-α, and blood pressure across 17 RCTs

Jafari et al., Food Science and Nutrition, 2025

View as image ↗

Five medicinal mushrooms have meaningful published research on chronic inflammation in humans or large population studies: Shiitake, Reishi, Lion's Mane, Cordyceps, and mixed mushroom consumption tracked as a dietary pattern. The evidence across those species tells a counterintuitive story. The mushroom most commonly sold as an anti-inflammatory supplement, Reishi (Ganoderma lucidum), failed to significantly reduce CRP or other inflammatory markers in a 2025 GRADE meta-analysis of 17 randomized controlled trials involving 971 participants.^[2] The mushroom with the best human clinical evidence for reducing inflammation markers is Shiitake, which most people simply eat as food.

That inversion is the central finding in the cross-species research on mushrooms and chronic inflammation. It matters because people searching for "mushrooms for chronic inflammation" are often deciding which supplement to buy. The species comparison here is built from human clinical evidence, not from preclinical data. Where only animal or cell culture data exists, that distinction is noted. For the molecular story of how mushrooms block inflammatory signaling through NF-kB and COX-2 pathways, see How Mushrooms Fight Inflammation: NF-kB, COX-2, and Beyond.

What Chronic Inflammation Is and Why CRP Is the Standard Marker

Chronic inflammation is different from the acute inflammation most people are familiar with. Acute inflammation is the swelling and redness around a cut or infection: it comes on fast, serves a purpose, and resolves. Chronic inflammation is lower-grade, long-lasting, and often symptomless. It's driven by metabolic dysfunction, poor diet, stress, visceral fat, gut dysbiosis, and aging, and it creates persistent background activation of the immune system.

CRP, or C-reactive protein, is a blood marker that rises when the liver detects ongoing inflammation. The American Heart Association classifies CRP below 1 mg/L as low cardiovascular risk, 1-3 mg/L as intermediate risk, and above 3 mg/L as high risk. Sustained elevated CRP predicts higher rates of heart disease, type 2 diabetes, and all-cause mortality independent of other risk factors. It's the standard endpoint in clinical trials testing whether an intervention actually reduces chronic systemic inflammation, because it's sensitive enough to detect real physiological change but also stable enough that transient fluctuations don't produce false positives.

CRP is produced by the liver in response to cytokines, particularly IL-6, which is released by immune cells and fat tissue when the body's inflammatory state is elevated. This means CRP doesn't directly cause inflammation; it reflects inflammation that's already ongoing elsewhere. Reducing CRP requires reducing the upstream cytokine signals, which requires changing the conditions that drive those signals: metabolic dysfunction, visceral fat, poor gut health, chronic stress, or infection. That chain of causation is why CRP is genuinely hard to move with supplementation alone, and why whole-food dietary patterns show stronger effects than isolated compounds in both the mushroom research and the broader anti-inflammatory research literature.

Five Species, One Ranking: The Cross-Species Evidence Summary

Below is where the research currently stands on mushrooms and chronic inflammation, structured by evidence quality.

Shiitake (Lentinula edodes): Best human evidence. One RCT (n=52, 4 weeks) showed CRP improvement alongside immune marker benefits in healthy young adults. Evidence type: human randomized controlled trial.

Mushrooms as dietary pattern: Strong associational evidence. A large Harvard prospective cohort found higher mushroom consumption associated with favorable cardiometabolic biomarkers, including inflammatory markers. Evidence type: observational cohort (causation cannot be established).

Reishi (Ganoderma lucidum): Promising preclinical, null clinical results. Rich preclinical evidence for anti-inflammatory mechanisms (NF-kB, cytokine suppression). But across 17 human RCTs pooled in a 2025 GRADE meta-analysis, no significant CRP effect. Evidence type: preclinical strong, clinical null.

Lion's Mane (Hericium erinaceus): In vitro evidence for metabolic inflammation. Cell culture data showing anti-inflammatory activity in the fat cell-macrophage interaction that drives obesity-related chronic inflammation. No human CRP trials published. Evidence type: preclinical only.

Cordyceps: Animal-model evidence. Polysaccharide extract reduced inflammatory markers alongside lipid parameters in hypertriglyceridemic rats. No human clinical data on inflammation specifically. Evidence type: animal model only.

Shiitake: The Best Human Evidence Comes From a Food, Not a Supplement

The most directly relevant clinical trial on mushrooms and chronic inflammation is a 2015 randomized controlled trial by Dai and colleagues, published in the Journal of the American College of Nutrition.^[1] Fifty-two healthy young adults were randomized to consume dried Shiitake mushrooms daily for 4 weeks. The comparison was baseline versus post-intervention in the same participants.

The results showed improvements across several immune measures: increased natural killer cell count and activity, increased proliferation of T-cells and B-cells, and a shift in cytokine production patterns toward a less inflammatory profile. CRP levels showed improvement consistent with reduced inflammation, though the change was modest. The participants were healthy adults without diagnosed inflammatory conditions, which means the results cannot be straightforwardly extrapolated to people with elevated baseline CRP or chronic inflammatory diseases.

What the Dai 2015 trial establishes: daily consumption of whole Shiitake mushrooms by healthy adults produces a measurable shift in immune activity and inflammation markers over 4 weeks. The dose was not a supplement, it was food. The intervention was not an isolated extract, it was the whole mushroom. That distinction may matter for why this trial showed a benefit when supplement trials for other species have not.

For a detailed look at the CRP clinical evidence across all mushroom species and what the mixed trial results mean for supplement decisions, see Medicinal Mushrooms and CRP Reduction: Clinical Evidence.

Reishi's Clinical Failure: 17 Trials, No Significant CRP Effect

Reishi is the mushroom most prominently marketed for immune support and anti-inflammatory effects. Its preclinical data is genuinely impressive. Reviews of Ganoderma lucidum's pharmacology document activity through NF-kB pathway inhibition, cytokine suppression, and triterpenoid-mediated anti-inflammatory effects.^[8] The mechanistic story from animal studies and cell culture is compelling.

The clinical story is something else entirely.

Jafari and colleagues published a 2025 GRADE systematic review and meta-analysis of Ganoderma lucidum clinical trials.^[2] They pooled 17 randomized controlled trials involving 971 participants. The findings: Reishi supplementation had no statistically significant effect on CRP, TNF-alpha (another inflammatory marker), blood pressure, lipid profile (LDL, HDL, triglycerides), fasting blood glucose, or liver enzymes. The GRADE assessment rated the evidence quality as "very low" across all outcomes, meaning even the non-significant results are uncertain.

This is the most rigorous clinical evaluation of Reishi available. It directly contradicts the claim, common across mushroom supplement marketing, that Reishi is an effective anti-inflammatory supplement. The preclinical mechanisms are real; the clinical translation, at doses and formulations used in human trials, has not materialized.

Three reasons could explain the gap between preclinical and clinical results. First, doses in animal studies are typically much higher than supplement doses relative to body weight. A rat receiving 200 mg/kg of an extract is getting a dose that doesn't map neatly onto a human taking 1-2 capsules daily. Second, the bioavailability of Reishi's active triterpenoids from commercial extracts varies substantially and is rarely characterized in clinical trial supplements. Third, Reishi's effects may be context-dependent: potentially relevant for specific high-inflammation conditions rather than reducing CRP in general populations.

The GRADE designation in the Jafari 2025 meta-analysis is not just a finding but a verdict on evidence quality. GRADE (Grading of Recommendations, Assessment, Development and Evaluations) is the framework that clinical guideline bodies use to decide how much weight to give research. A GRADE rating of "very low quality evidence" means that the available trials are small, heterogeneous, or at high risk of bias, making the overall estimates uncertain even when pooled. This rating for Reishi inflammation trials doesn't mean the clinical trials were bad science; it means the field hasn't yet produced the rigorous, large, well-controlled trials that would give confident clinical guidance.

The Venturella 2021 comprehensive review of Reishi's properties acknowledged inconsistency in human clinical evidence while documenting the preclinical pharmacological profile.^[8] The Jafari 2025 meta-analysis resolves that inconsistency: across 17 trials, the net effect is zero.

Lion's Mane, Cordyceps, and the Preclinical Evidence

Lion's Mane has no published human clinical trials specifically examining CRP. What it does have is in vitro evidence for anti-inflammatory effects in the specific cellular environment that drives chronic, low-grade inflammation in people with metabolic syndrome.

Mori and colleagues tested H. erinaceus extract in a coculture system: fat cells (adipocytes) and macrophages grown together.^[3] This coculture better mimics the adipose tissue environment in obesity, where macrophages infiltrate fat deposits and generate persistent cytokine production. The extract reduced inflammatory cytokines produced by the activated macrophages in this system. The finding is relevant to metabolic inflammation specifically, not inflammation in general.

Jeong and colleagues' review of Lion's Mane's pharmacological profile confirmed broader anti-inflammatory and anti-allergic effects through NF-kB and COX-2 suppression, placing it within the same mechanistic framework as other anti-inflammatory mushrooms.^[4] These are genuine pharmacological effects; they simply haven't been translated into CRP trials in humans.

Cordyceps' inflammatory evidence is even more preliminary. Lu and colleagues found that Cordyceps sinensis polysaccharide reduced inflammatory markers alongside lipid parameters in rats with high triglycerides.^[5] The connection to inflammation is partly through the inflammation-lipid interplay common in metabolic syndrome. Whether this translates to human CRP reduction at any achievable supplement dose is unknown. No human trials have tested this.

For the IL-6 angle specifically, which is upstream of CRP production in the liver, see Mushroom Compounds and IL-6 Reduction.

The Bigger Picture: Dietary Mushrooms vs. Mushroom Supplements

The most important finding for people trying to reduce chronic inflammation through mushrooms may be the one that gets the least attention in supplement marketing.

Lee and colleagues published a 2019 prospective cohort analysis using data from two large Harvard studies: the Nurses' Health Study and the Health Professionals Follow-up Study, together tracking tens of thousands of participants over many years.^[6] Higher mushroom consumption was associated with favorable profiles across cardiometabolic biomarkers, including markers relevant to inflammation. This was observational: it cannot prove that mushrooms caused the benefit. But the scale of the cohort and consistency of the associations add weight to the idea that regular mushroom consumption as food produces measurable population-level effects.

Thapa and colleagues' 2023 systematic review of mushroom consumption and cardiometabolic risk found suggestive but inconsistent associations between mushroom consumption and high-sensitivity CRP across a mix of cohort studies and clinical trials.^[7] One clinical trial in healthy adults following a Mediterranean diet found no significant CRP change when mushrooms were added. The reviewers concluded that the evidence was promising but heterogeneous, meaning results varied enough across studies that a clean yes-or-no answer wasn't possible.

Taken together, the cross-species evidence suggests a pattern: dietary mushroom consumption, tracked in large population studies, correlates with better inflammatory biomarker profiles. Isolated mushroom supplements, tested in controlled trials, show inconsistent results. This doesn't mean supplements are useless, but it suggests the benefit may come from eating mushrooms as part of a whole-food dietary pattern rather than from taking capsules.

For an exploration of how beta-glucans (the key immune-active compounds in most edible mushrooms) may produce lasting immune reprogramming that contributes to this dietary pattern effect, see How Beta-Glucans Epigenetically Reprogram Immune Cells.

For the CRP-specific question ("can mushrooms lower my CRP?"), see Mushrooms and C-Reactive Protein: Can Fungi Lower Chronic Inflammation Markers?.

The Bottom Line

Across five mushroom species studied for chronic inflammation, the evidence hierarchy is clear but inconvenient for supplement marketing: Shiitake (eaten as food) has the strongest human clinical data; Reishi (the most-marketed anti-inflammatory supplement) showed no significant CRP reduction across 17 clinical trials in a 2025 GRADE meta-analysis; Lion's Mane and Cordyceps have preclinical evidence only. The largest population-level signal comes from dietary mushroom consumption in cohort studies, suggesting that eating mushrooms regularly as food may produce better inflammatory biomarker outcomes than taking isolated mushroom supplements.

Frequently Asked Questions

Which mushrooms are best for chronic inflammation?

Based on human clinical evidence, Shiitake has the strongest data: a 2015 randomized trial in 52 healthy adults found daily Shiitake consumption improved immune markers and shifted cytokine profiles toward less inflammation over 4 weeks. Reishi is widely marketed for inflammation but showed no significant effect on CRP in a 2025 meta-analysis of 17 clinical trials. Lion's Mane and Cordyceps have only preclinical evidence for inflammation specifically.

Can mushrooms reduce systemic inflammation?

The evidence is mixed and depends on the form. Eating mushrooms regularly as part of a healthy diet is associated with favorable inflammatory biomarker profiles in large prospective cohort studies. Mushroom supplements (especially Reishi) have not consistently reduced CRP in controlled clinical trials. The honest summary: dietary mushrooms are better supported than mushroom supplement capsules for reducing systemic inflammation markers like CRP.

Do medicinal mushrooms lower inflammatory markers?

In laboratory and animal studies, yes: multiple species reduce NF-kB signaling, COX-2 activity, and pro-inflammatory cytokines. In human clinical trials, the picture is more complicated. Shiitake shows a positive signal in one trial. Reishi failed to show significant effects on CRP, TNF-alpha, or other inflammatory markers across 17 trials (n=971). The most studied "medicinal mushroom" for inflammation has the most disappointing clinical track record.

Which mushroom is most anti-inflammatory?

In preclinical research, Reishi (Ganoderma lucidum) has the most extensive anti-inflammatory mechanistic evidence. In human clinical research, Shiitake is the only species with a randomized controlled trial showing CRP reduction. The species most often recommended and sold for this purpose (Reishi) is not the species with the best human evidence. If anti-inflammatory effect in humans is the criterion, Shiitake has the stronger clinical case.

Is there clinical evidence that mushrooms reduce inflammation?

Yes, but it's limited and species-specific. The clearest human evidence is a single Shiitake RCT (52 participants, 4 weeks, daily whole mushroom consumption). A large prospective cohort found higher mushroom consumption associated with better inflammatory biomarker profiles, though observational data cannot prove causation. A 2023 systematic review of mushroom consumption and cardiometabolic markers found suggestive but inconsistent results for CRP specifically.

Sources & References

1. 1RTHM-00368·Dai, Xiaoshuang et al. (2015). “Consuming Lentinula edodes (Shiitake) Mushrooms Daily Improves Human Immunity: A Randomized Dietary Intervention in Healthy Young Adults..” Journal of the American College of Nutrition.Study breakdown →PubMed →↩
2. 2RTHM-02098·Jafari, Ali et al. (2025). “The Nutritional Significance of Ganoderma lucidum on Human Health: A GRADE-Assessed Systematic Review and Meta-Analysis of Clinical Trials..” Food science & nutrition.Study breakdown →PubMed →↩
3. 3RTHM-00726·Mori, Koichiro et al. (2015). “The Anti-Inflammatory Effects of Lion's Mane Culinary-Medicinal Mushroom, Hericium erinaceus (Higher Basidiomycetes) in a Coculture System of 3T3-L1 Adipocytes and RAW264 Macrophages..” International journal of medicinal mushrooms.Study breakdown →PubMed →↩
4. 4. Source details for this reference are not yet available.
5. 5. Source details for this reference are not yet available.
6. 6RTHM-00567·Lee, Dong Hoon et al. (2019). “Mushroom consumption, biomarkers, and risk of cardiovascular disease and type 2 diabetes: a prospective cohort study of US women and men..” The American journal of clinical nutrition.Study breakdown →PubMed →↩
7. 7. Source details for this reference are not yet available.
8. 8. Source details for this reference are not yet available.